Liver cancer treatment showdown halted early
NCT ID NCT05537402
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This study aimed to compare two standard first-line treatments for people with large, intermediate-stage liver cancer (HCC) that cannot be surgically removed. One group received a combination of immunotherapy (atezolizumab) and targeted therapy (bevacizumab), while the other group received a locoregional procedure (TACE or TARE). The goal was to see which approach better delayed cancer progression. The study was terminated early after enrolling only one participant, so no meaningful conclusions could be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.